• Type:
  • Category:

Carl Zeiss Meditec AG Financial Results H1 2022 /23 | Achieving Double-Digit Growth with CEO and CFO



In this insightful video presentation, Carl Zeiss Meditec AG, a leading medical technology company, reports on its performance during the first half of the fiscal year 2022/23. Despite challenging circumstances, such as the ongoing COVID-19 pandemic and strained global supply chains, the company achieved a remarkable 13.9% growth, generating around €974.5m in revenue. However, this robust revenue growth was offset by a decline in earnings before interest and taxes (EBIT), which dropped to €143.9m from the prior year’s €177.3m, primarily due to an unfavourable product mix and rising operational costs.


Notably, the Americas region recorded the most substantial growth, with revenue surging by an impressive 27.6%. The company’s strategic business units (SBUs) in Ophthalmology and Microsurgery contributed significantly to this growth. In contrast, the EBIT margin shrank to 14.8% from 20.7% in the previous year, largely due to the pandemic’s impact on the Chinese market, increased investment in research and development, higher procurement costs, and rising labour costs.


Despite the decrease in EBIT, the company’s CEO, Dr Markus Weber, expresses satisfaction with the company’s performance and reaffirms the company’s commitment to strategic investments in research and development, supply chain improvements, and shortening delivery times. Looking ahead, Carl Zeiss Meditec AG has consolidated its projections for the fiscal year 2022/23, expecting revenue to increase to around €2.1 billion, with the EBIT margin anticipated to be between 17-20%.

Company Profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,224 employees worldwide, the Group generated revenue of €1,902.8m in fiscal year 2021/22 (to 30 September).


The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float.


The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

Carl Zeiss Meditec AG

Goeschwitzer Strasse 51-52

Jena 07745, Germany

phone +49 3641 220 116


  • About the 6M – 2022/23
  • Current Challenges
  • Expectations for H2 2022/23



Dr. Markus Weber
CEO | Carl Zeiss Meditec AG

Justus Felix Wehmer
CFO | Carl Zeiss Meditec AG

Sebastian Frericks
Head IR | Carl Zeiss Meditec AG



This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

More Elevator Pitches

More Company Presentations

Reviews for Carl Zeiss Meditec AG Financial Results H1 2022 /23 | Achieving Double-Digit Growth with CEO and CFO

There are currently no reviews for Carl Zeiss Meditec AG Financial Results H1 2022 /23 | Achieving Double-Digit Growth with CEO and CFO
Scroll to top